Ionis Pharmaceuticals (IONS) Form 4 IONIS PHARMACEUTICALS / STANLEY T CROOKE ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

CROOKE STANLEY T

(Last) (First) (Middle)

C/O IONIS PHARMACEUTICALS, INC.

2855 GAZELLE COURT

(Street)

CARLSBAD, CA 92010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Exec Chairman of the Board

3. Date of Earliest Transaction (Month/Day/Year)
11/23/2020

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/23/2020	11/23/2020	M		500(1)	A	$39.87	2,081	I	by wife
Common Stock	11/23/2020	11/23/2020	S		500(2)	D	$50	1,581	I	by wife
Common Stock	11/23/2020	11/23/2020	M		11,600(3)	A	$39.87	13,621	D
Common Stock	11/23/2020	11/23/2020	S		11,600(4)	D	$50.11(5)	2,021	D
Common Stock	11/24/2020	11/24/2020	M		2,590(3)	A	$39.87	4,611	D
Common Stock	11/24/2020	11/24/2020	S		2,590(4)	D	$50.83(6)	2,021	D
Common Stock								650,391	I	by Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$39.87	11/23/2020	11/23/2020	M			500	01/02/2015	01/01/2021	Common Stock	0	$0.0	0	I	by wife
Non-Qualified Stock Option (right to buy)	$39.87	11/23/2020	11/23/2020	M			11,600	01/02/2015	01/01/2021	Common Stock	0.0	$0.0	15,580	D
Non-Qualified Stock Option (right to buy)	$39.87	11/24/2020	11/24/2020	M			2,590	01/02/2015	01/01/2021	Common Stock	0	$0	12,990	D

Explanation of Responses:

1. Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person's wife on March 13, 2019.

2. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person's wife on March 13, 2019.

3. Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2019.

4. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2019.

5. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.25, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) of this Form 4.

6. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.50 to $51.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) of this Form 4.

Remarks:

	/s/Patrick R. O'Neil, attorney-in-fact	11/25/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.